BioSpace News Archive

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) inject

Avrio Health L.P., a subsidiary of Purdue Pharma L.P., has donated shipments of Betadine Solution and Surgical Scrub to Direct Relief, advancing the company’s previous commitment to donate $1.6 million worth of Betadine antiseptic products for use by frontline healthcare workers.

Dr. Stephen Brigido has joined NEXGEL’s Scientific Advisory Board. Dr. Brigido will participate with and advise the Company regarding its clinical and over-the-counter commercial development of new products created from NEXGEL’s hydrogel technology.

-- Offer price increased from €39.00 to €43.00 per QIAGEN share in cash -- Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares -- QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares

3M is sharing results of the global efforts the company launched in March to combat fraud connected to the COVID-19 pandemic.

New TTS Stent Allows Palliative Treatment of Esophageal Stricture and Trachea-Esophageal Fistula Caused by Malignant Tumors

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2020 financial results Friday, August 7, 2020. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in the live call by t

Agent Capital, a majority woman-owned international life sciences investment firm supporting disruptive healthcare companies, announced the appointment of industry veteran Jacopo Leonardi as Partner

- An estimated 15% to 20% of the Turkish population suffers from the difficulty of conceiving - “As the world’s only Intravaginal Culture System, INVOcell, a streamlined treatment solution, is uniquely positioned to address the challenges within the infertility industry.” [16-July-2020] SARASOTA, Fla. , July 16, 2020 /PRNewswire/ -- INVO Bioscience

Promega Corporation’s Maxwell ® RSC 48 Instrument and Maxwell ® RSC Viral Total Nucleic Acid Purification Kit (Maxwell Extraction System) are now in the Centers for Disease Control and Prevention’s (CDC) COVID-19 diagnostic protocol for emergency use. In a letter dated July 13, 2020, the U.S. Food and Drug Administration (FDA) auth